Book 2023

Managing the Drug Discovery Process: Insights and advice for students, educators, and practitioners, Second Edition

Managing the Drug Discovery Process: Insights and advice for students, educators, and practitioners, Second Edition
Journal · pp. 1-639
Abstract

Managing the Drug Discovery Process, Second Edition thoroughly examines the current state of pharmaceutical research and development by providing experienced perspectives on biomedical research, drug hunting and innovation, including the requisite educational paths that enable students to chart a career path in this field. The book also considers the interplay of stakeholders, consumers, and drug firms with respect to a myriad of factors. Since drug research can be a high-risk, high-payoff industry, it is important to students and researchers to understand how to effectively and strategically manage both their careers and the drug discovery process. This new edition takes a closer look at the challenges and opportunities for new medicines and examines not only the current research milieu that will deliver novel therapies, but also how the latest discoveries can be deployed to ensure a robust healthcare and pharmacoeconomic future. All chapters have been revised and expanded with new discussions on remarkable advances including CRISPR and the latest gene therapies, RNA-based technologies being deployed as vaccines as well as therapeutics, checkpoint inhibitors and CAR-T approaches that cure cancer, diagnostics and medical devices, entrepreneurship, and AI. Written in an engaging manner and including memorable insights, this book is aimed at anyone interested in helping to save countless more lives through science. A valuable and compelling resource, this is a must-read for all students, educators, practitioners, and researchers at large—indeed, anyone who touches this critical sphere of global impact—in and around academia and the biotechnology/pharmaceutical industry. © 2023 Elsevier Ltd. All rights reserved.

Keywords

Author Keywords

Not provided

Index Keywords

Author Affiliations
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, United States
Arizona State University, Tempe, AZ, United States
Funding & Acknowledgements
No funding information
References 10 References
1 Balaram, Padmanabhan, Drug discovery: Myth and reality, Current Science, 87, 7, pp. 847-848, (2004)
2 Creative Destruction Why Companies that are Built to Last Underperform the Market and how to Successfully Transform Them, (2001)
3 Irwin, Michael H., Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases, Drug Development Research, 77, 3, pp. 109-123, (2016)
4 Kornberg, Arthur, The Two Cultures: Chemistry and Biology, Biochemistry, 26, 22, pp. 6888-6891, (1987)
5 Moos, Walter H., Microbiota and Neurological Disorders: A Gut Feeling, BioResearch Open Access, 5, 1, pp. 137-145, (2016)
6 Moos, Walter H., Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia, Drug Development Research, 77, 2, pp. 53-72, (2016)
7 Śmietana, Katarzyna, Trends in clinical success rates, Nature Reviews Drug Discovery, 15, 6, pp. 379-380, (2016)
8 Sneader, Walter E., Drug Discovery: A History, Drug Discovery: A History, pp. 1-468, (2006)
9 Cleary, Ekaterina Galkina, Contribution of NIH funding to new drug approvals 2010–2016, Proceedings of the National Academy of Sciences of the United States of America, 115, 10, pp. 2329-2334, (2018)
10 Dolgin, Elie, The tangled history of mRNA vaccines, Nature, 597, 7876, pp. 318-324, (2021)
Quick Actions
Full Text via DOI
Citation Metrics
0
Times Cited (Scopus)

References 10
Document Identifiers